The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC.
 
Diana S. Osorio
Employment - ICON Clinical Research
 
Maxim Yankelevich
No Relationships to Disclose
 
Wafik Tharwat Zaky
No Relationships to Disclose
 
Lucie Lafay-Cousin
No Relationships to Disclose
 
Ashley S. Margol
Consulting or Advisory Role - Day One Biopharmaceuticals
 
Stephanie Toll
No Relationships to Disclose
 
Lina Quiroz
No Relationships to Disclose
 
Javier E. Fox
No Relationships to Disclose
 
Derek Hanson
No Relationships to Disclose
 
Sharon L. Gardner
No Relationships to Disclose
 
Michael Prados
Stock and Other Ownership Interests - Quadriga Biosciences
Research Funding - Bristol-Myers Squibb (Inst); Day One Therapeutics (Inst); Genentech/Roche (Inst); Novartis (Inst); Oncoceutics (Inst); Regeneron (Inst)
 
Sabine Mueller
Consulting or Advisory Role - Roche
Research Funding - Blueprint Medicines (Inst); Bristol Meyer Scribbs (Inst); Chimerix (Inst); Curis Pharamceuticals (Inst); DayOne Pharmaceuticals (Inst); Pfizer (Inst); Regeneron (Inst); SonaCare Medical (Inst)
 
Jonathan L. Finlay
No Relationships to Disclose